BioSentinel, Inc was founded to create novel detection systems, to develop high specificity and sensitivity portable, biosensor devices and to discover antagonists for bioterrorism by use of botulinum neurotoxins (BoNTs). BioSentinel's proprietary rapid detection technology addresses not only the US biodefense mandate but also the needs of pharmaceutical companies who sell botulinum neurotoxin for FDA approved therapies and have ongoing programs for novel clinical applications.